Myriad Genetics Inc (MYGN)
Myriad Genetics Inc is a biotechnology company specializing in molecular diagnostics and genetic testing. It develops and commercializes tests that assess risk for various diseases, including cancer, women's health conditions, and other hereditary disorders. The company focuses on personalized medicine solutions to help guide clinical decision-making and improve patient outcomes.
Company News
Myriad Genetics added F8 and FXN genes to its Foresight® Carrier Screen Universal Plus Panel, enhancing genetic screening capabilities for hemophilia A and Friedreich's ataxia, while maintaining compliance with ACMG recommendations.
Myriad Genetics, Inc. (MYGN) is facing a securities fraud investigation after its Q1 2025 financial results showed a decline in revenue and reduced guidance for the year, causing a significant drop in its stock price.
Myriad Genetics has secured a second foundational patent for its tumor-informed, high-definition, molecular residual disease (MRD) assay, Precise MRD. The new patent covers the company's breakthrough platform MRD technology, which enables highly sensitive and specific tumor-informed, sequencing-based MRD assays. This development strengthens Myria...
Everyone is watching the banks, but what about healthcare. It's breaking out, says this strategist.
The genetic-testing company announced an acquisition and lowered its guidance.